AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL)

CUSIP: 05337G107

Q1 2015 13F Holders as of 31 Mar 2015

Type / Class
Equity / COM
Total 13F shares
15,859,361
Share change
+2,354,170
Total reported value
$641,579,016
Put/Call ratio
25%
Price per share
$40.52
Number of holders
111
Value change
+$75,031,347
Number of buys
80
Number of sells
36

Quarterly Holders Quick Answers

What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q1 2015

As of 31 Mar 2015, AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by 111 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,859,361 shares. The largest 10 holders included FMR LLC, DEERFIELD MANAGEMENT CO, VHCP Management, LLC, JPMORGAN CHASE & CO, BlackRock Fund Advisors, Tourbillon Capital Partners LP, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, Redmile Group, LLC, and Invesco Ltd.. This page lists 111 institutional shareholders reporting positions in this security for the Q1 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.